Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 14, 2021 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021GAITHERSBURG, Md. and CALGARY, Alberta, Sept....
August 25, 2021 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential...
August 23, 2021 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
July 29, 2021 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second...
July 29, 2021 07:25 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview...
July 26, 2021 09:01 ET | Source: Emergent BioSolutions

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes...
July 15, 2021 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial...
June 11, 2021 16:35 ET | Source: Emergent BioSolutions

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md., June 11, 2021 (GLOBE...
May 26, 2021 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate

A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19...
May 06, 2021 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live...